KAKEN PHARMACEUTICAL CO.,LTD. (4521.T)
772JPY
1:00am EST
¥4 (+0.52%)
¥768
¥768
¥773
¥766
275,000
345,500
¥1,011
¥734
4521.T
About
Overall
| Beta: | 0.38 |
| Market Cap (Mil.): | ¥74,414.78 |
| Shares Outstanding (Mil.): | 98.17 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| 4521.T | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 3.59 | 4.67 |
| EPS (TTM): | -- | -- | -- |
| ROI: | -- | 1.80 | 2.82 |
| ROE: | -- | 2.41 | 3.52 |
Kaken Pharmaceutical <4521.T>-6mth group results
6 months ended 6 months ended Full year to Full year ended
Kaken Pharmaceutical <4521.T>-1qtr group results
3 months ended 3 months ended 6 months to Year to
Kaken Pharmaceutical <4521.T>-2008/09 parent
Year ended Year ended Year to Six months to
Kaken Pharmaceutical <4521.T>-2008/09 group
Year ended Year ended Year to Six months to
Japanese stocks likely to rebound after U.S. data
TOKYO, Aug 28 (Reuters) - Japanese stocks are likely to rebound on Thursday, as strong data on U.S. durable goods orders are expected to help ease concern about the flagging U.S. economy.
RESEARCH ALERT-Daiwa Research ratings(Jul 1)
TOKYO, July 1 (Reuters) - Follows is a list of ratings assigned by Daiwa Institute of Research Ltd on Tuesday. -------------------------------------------------- First time rated:
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
